Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Obesity · Type 2 diabetes

NovoThirteen

NovoThirteen clinical programs — 94 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bagsværd, JP HQ
PMDA registrant Type
Company details
Status
Public
HQ
Bagsværd, JP
Programs
94
Drugs
67
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

NovoThirteen projects

94 ClinicalTrials.gov programs sponsored by NovoThirteen.

NovoThirteen has 94 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

94 programs

Clinical programs

Page 1 of 2

  1. 4202-HEM-301

    NovoThirteen

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  2. Etavopivat A 200 mg

    NovoThirteen

    Sickle Cell Disease and Thalassaemia

    phase 3 small molecule active

    1 trial

  3. NN1436-7724

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  4. NN1436-8182

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  5. NN1535-8377

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  6. NN6019-4958

    NovoThirteen

    Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy

    phase 3 small molecule active

    1 trial

  7. NN6535-4725

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  8. NN6535-4730

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  9. NN6535-7519

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  10. NN7415-4307

    NovoThirteen

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  11. NN7415-4311

    NovoThirteen

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  12. NN7415-4616

    NovoThirteen

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  13. NN8022-4392

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  14. NN8640-4263

    NovoThirteen

    Growth Hormone Deficiency in children

    phase 3 small molecule active

    1 trial

  15. NN8640-4467

    NovoThirteen

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    phase 3 small molecule active

    1 trial

  16. NN9388-4895

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  17. NN9388-7637

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  18. NN9388-7741

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  19. NN9490-8021

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  20. NN9490-8024

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  21. NN9490-8025

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  22. NN9490-8026

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  23. NN9490-8028

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  24. NN9490-8266

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  25. NN9490-8293

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  26. NN9490-8294

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  27. NN9490-8559

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  28. NN9535-4352

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  29. NN9535-4801

    NovoThirteen

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

  30. NN9833-8242

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  31. NN9833-8243

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  32. NN9838-4608

    NovoThirteen

    Overweight and obesity

    phase 3 other active

    1 trial

  33. NN9838-4609

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  34. NN9838-4942

    NovoThirteen

    Cardiovascular disease

    phase 3 small molecule active

    1 trial

  35. NN9838-7749

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  36. NN9838-7859

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  37. NN9924-4437

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  38. NN9931-4553

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  39. Placebo (ziltivekimab), ziltivekimab

    NovoThirteen

    Acute myocardial infarction

    phase 3 small molecule active

    1 trial

  40. Placebo (ziltivekimab), ziltivekimab

    NovoThirteen

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  41. Placebo, Etavopivat A 200 mg

    NovoThirteen

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  42. ziltivekimab, Placebo (ziltivekimab C)

    NovoThirteen

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  43. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  44. NN6019-7565

    NovoThirteen

    Participants with transthyretin amyloid cardiomyopathy (ATTR CM)

    phase 2 small molecule active

    1 trial

  45. NN6706-8212

    NovoThirteen

    Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  46. NN6706-8282

    NovoThirteen

    Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  47. NN7533-4470

    NovoThirteen

    Sickle cell disease

    phase 2 small molecule active

    1 trial

  48. NN8640-4245

    NovoThirteen

    SGA - small for gestational age children

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does NovoThirteen have?

94 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.